FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

Pharm Exec's Emerging Pharma Leaders 2016

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

FDA's accelerated drug approvals often lack confirmatory evidence

SEC Filing Vistagen Therapeutics, Inc

U.S. FDA Approved Drugs from 2015–June 2020: A Perspective

FDA Faces Hard Decisions After Fast-Tracking Unproven Drugs

Pharmaceutical payments to psychiatrists and betrayal of the

FDA fast-tracking approval of new drugs — fewer trials, less info

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

FDA's accelerated drug approvals often lack confirmatory evidence

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

FDA rules Otsuka marketing claim overstates Rexulti efficacy

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for